CAJ | 학술논문

目的：观察与分析冠状动脉慢血流患者采用阿托伐他汀治疗临床疗效及对患者血脂、血清超敏 C 反应蛋白及内皮功能指标水平影响。方法：选取本院86例冠状动脉慢血流患者按照治疗方法不同分组为对照组与观察组，各43例。对照组采用阿司匹林和硝酸酯类药物及曲美他嗪治疗；观察组于对照组治疗基础上加用阿托伐他汀治疗。比较2组临床疗效及治疗前后血脂、血清超敏 C 反应蛋白(hs-CRP)及内皮功能指标水平变化情况。结果：治疗后，2组患者 hs-CRP 及血脂水平较治疗前明显下降，但观察组下降更为显著；2组患者治疗后内皮素-1(ET-1)及白细胞介素-6(IL-6)较治疗前均明显下降，而一氧化氮(NO)水平较治疗前明显升高，且观察组改善各项指标改善较对照组明显。观察组临床治疗有效率为86.05%(37/43)明显高于对照组58.14%(25/43)。2组均未现明显不良反应。结论：临床采用阿托伐他汀辅助治疗可疗效显著且安全。
목적：관찰여분석관상동맥만혈류환자채용아탁벌타정치료림상료효급대환자혈지、혈청초민 C 반응단백급내피공능지표수평영향。방법：선취본원86례관상동맥만혈류환자안조치료방법불동분조위대조조여관찰조，각43례。대조조채용아사필림화초산지류약물급곡미타진치료；관찰조우대조조치료기출상가용아탁벌타정치료。비교2조림상료효급치료전후혈지、혈청초민 C 반응단백(hs-CRP)급내피공능지표수평변화정황。결과：치료후，2조환자 hs-CRP 급혈지수평교치료전명현하강，단관찰조하강경위현저；2조환자치료후내피소-1(ET-1)급백세포개소-6(IL-6)교치료전균명현하강，이일양화담(NO)수평교치료전명현승고，차관찰조개선각항지표개선교대조조명현。관찰조림상치료유효솔위86.05%(37/43)명현고우대조조58.14%(25/43)。2조균미현명현불량반응。결론：림상채용아탁벌타정보조치료가료효현저차안전。
objective Observation and analysis of patients with coronary slow flow of atorvastatin treatment efficacy and patient blood lipids, serum high-sensitivity C-reactive protein levels and endothelial function parameters influence. Methods Select hospital 86 cases diagnosed as coronary slow flow of patients grouped according to the different treatment methods for the control group and the observation group, 43 cases each. The control group using aspirin and nitrates and trimetazidine treat-ment; observation group therapy based on the use of atorvastatin treatment in the control group. Comparison of the clinical effi-cacy of the two groups before and after treatment lipids, serum high-sensitivity C-reactive protein (hs-CRP) levels and changes in endothelial function parameters. Results After treatment, the two groups of patients hs-CRP and lipid levels before treatment significantly decreased, but the observation group decreased more significantly; group 2 patients after endothelin -1 (ET-1) and interleukin -6 (IL-6) were significantly lower than before treatment, and nitric oxide (NO) level was significantly higher than that before treatment, and the improvement of the indicators to improve the observation group than in the control group was sig-nificantly. Clinical observation group effective rate 86.05% (37/43) was significantly higher than 58.14% (25/43). Two groups were not significant adverse reactions now. Conclusion Clinical use of atorvastatin therapy can assist a significant effect and safety.